Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Centre Francois Baclesse
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Patient over 18 years of age
Patients with anti-aromatases in adjuvant treatment of breast cancer
Menopausal women
Treatment with aromatase inhibitors (anti-aromatase, AA) initiated for more than 3 months. In the case of a change in anti-aromatase, the last treatment must be started for more than 3 months.
Musculoskeletal pain appearing or increased under AA:
Overall pain score of QCD ≥3 (on a scale of 0 to 10)
Pain on at least 2 sites
Pain for at least 3 months
History of radiotherapy and / or adjuvant chemotherapy authorized
Patients may have received tamoxifen
Patient affiliated to a social security system
Patient mastering the French language and able to complete the evaluation questionnaires
Free and Informed Consent
You may not be if
Patients who have already undergone treatment in auriculotherapy for the same indication
Patient benefiting at the same time from a PNCAVT (acupuncture or homeopathy) for musculoskeletal pain
Wearing hearing aids hindering the placement of semi-permanent needles (ASP)
Wearing of a valve prosthesis
Patient under guardianship or unable to give informed consent
Patient unable to undergo medical follow-up for geographical, social or psychopathological reasons
Clareo Health | Phase 3 Study Randomized Evaluating the Efficacy of Auriculotherapy in Patients With Musculoskeletal Pain by Aromatase Inhibitors
